Envoy Medical Inc., a hearing health company specializing in fully implanted hearing devices, announced that its pivotal clinical trial for the fully implanted Acclaim® Cochlear Implant is progressing as planned. All 10 participants in the first stage of the trial have successfully completed their one-month follow-up visits, with investigational sites reporting that the visits are proceeding as expected. The participants are able to hear without externally worn devices, and no serious adverse events have been reported. Envoy Medical is encouraged by the positive momentum and is considering accelerating plans for expansion and commercialization of the device. Further updates on the trial will be provided to the shareholder community.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.